Breaking News

Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases

The federal government yesterday asked the federal appeals court in Washington, D.C., to review a lower court's Nov. 5 joint ruling in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers

Read More »

John Thune, Senate’s No. 2 Republican and Strong 340B Provider Ally, Weighs Retirement

U.S. Senate Minority Whip John Thune (R-S.D.), a strong 340B covered entity ally, is considering not running for re-election in 2022. | Gage Skidmore/Flickr

South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report.  It would be a significant blow to 340B providers who have counted

Read More »

Citing Omicron Wave, 340B Coalition Weighs Making Winter Conference a Hybrid Live/Virtual Event

Citing concerns about COVID-19's Omicron variant, the 340B Coalition is considering turning its Jan. 31–Feb. 2 in-person winter conference into a hybrid in-person/virtual event.

The 340B Coalition said yesterday it is “actively exploring the potential for a hybrid [winter 2022] conference that would allow attendance in-person or virtually for those that cannot attend in-person.”

The coalition, composed of 13 groups that represent 340B covered

Read More »

N.Y. and Va. Health Centers Say Discovery Should Continue in their Novel 340B-Related Federal Lawsuit

The federal district court for western New York is hearing two 340B health centers' antitrust lawsuit against insulin and diabetes drug makers.

New York State and Virginia health centers asked a federal district judge on Monday to deny four insulin and diabetes drug manufacturers’ motion to pause fact-finding in the health centers’ antitrust suit stemming from the companies’ 340B contract pharmacy policies.

Read More »

Novo Nordisk and Sanofi Have Jan. 26 Deadline to File Opening Briefs in 340B Contract Pharmacy Appeal

The U.S. Third Circuit Court of Appeals will hear Novo Nordisk and Sanofi's 340B contract pharmacy lawsuits in tandem, just as a lower court did.

A federal appeals court in Philadelphia has given drug manufacturers Novo Nordisk and Sanofi a Jan. 26 deadline to file briefs seeking reversal of parts of a district judge’s Nov. 5 joint decision in the two companies’ 340B contract pharmacy

Read More »

Boehringer Ingelheim Extends 340B Contract Pharmacy Restrictions to Previously Exempt Specialty Drug Ofev

Boehringer Ingelheim extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

Drug manufacturer Boehringer Ingelheim (BI) this month extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

BI announced its new 340B pricing policy in late June. Effective Aug.

Read More »

HRSA Adds Three Days to 1Q 340B Registration Period

The first 340B covered entity registration period of the year will be Jan. 1-18, 2022, for an effective start date of April 1, 2022.

The first 340B covered entity registration period of the year will be Jan. 1-18, 2022, for an effective start date of April 1, 2022.

Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during the period

Read More »

More Than 850 Hospitals Ask Feds to Appeal Judge’s 340B Contract Pharmacy Ruling

850+ hospitals in the 340B program sent the HHS secretary a letter yesterday asking the government to appeal a judge’s 340B contract pharmacy ruling.

Just over 850 hospitals in the 340B program asked the federal government yesterday to appeal a judge’s Nov. 5 ruling that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and others use contract pharmacies. They

Read More »

Provider Groups Pan Lilly’s 340B Contract Pharmacy Policy Change

Groups representing health care providers have panned Lilly's recent 340B contract pharmacy policy change.

Groups representing 340B health centers, Ryan White clinics, and hospitals panned drug manufacturer Lilly’s recent decision to amend its prohibition on 340B pricing when providers use contract pharmacies to dispense drugs to patients.

Lilly told drug wholesaler AmerisourceBergen on

Read More »

Is There a New 340B Stakeholder Group for Pharma Companies?

A new infographic by a drug industry consultant indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

The infographic came to light Sunday. It includes

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live